Olsalazine

Introduction Overview

Generic Name

olsalazine

Brand Name

Dipentum

Dosage Form

Oral capsule

Drug Class

5-aminosalicylates

Pharmacokinetics

Absorption:
Olsalazine, administered orally as Dipentum capsules, undergoes minimal absorption in the upper gastrointestinal tract due to its formulation designed to target the colon. Following oral administration, olsalazine remains largely intact until it reaches the terminal ileum and colon, where it is acted upon by colonic bacteria. Enzymatic cleavage by bacterial azoreductases converts olsalazine into its active moiety, 5-aminosalicylic acid (5-ASA or mesalamine), enabling localized therapeutic effects within the colon. This colonic targeted activation minimizes systemic absorption and reduces systemic side effects, as demonstrated in pharmacokinetic studies showing low plasma concentrations of 5-ASA following olsalazine dosing.

Distribution:
The absorbed fraction of 5-ASA resulting from olsalazine metabolism distributes moderately into systemic circulation, with preferential localization in colonic mucosal tissues. Protein binding of 5-ASA in plasma is approximately 43–78%, mainly to albumin, which may influence its volume of distribution. The tissue distribution facilitates superficial mucosal anti-inflammatory activity, critical for ulcerative colitis management. The limited systemic bioavailability further contributes to a favorable safety profile by restricting systemic exposure.

Metabolism:
Olsalazine itself is a prodrug not extensively metabolized by human enzymes but converted primarily by colonic bacterial azoreductases into two molecules of 5-aminosalicylic acid. Once released, 5-ASA undergoes phase II metabolic conjugation in the liver and intestinal mucosa, predominantly through N-acetylation forming N-acetyl-5-ASA, a pharmacologically inactive metabolite. Genetic polymorphisms in N-acetyltransferase enzymes may affect the rate of metabolism and thus influence individual therapeutic responses and adverse event profiles. Studies highlight the significance of metabolism in modulating efficacy and toxicity.

Elimination:
Elimination of olsalazine-derived 5-ASA and its metabolites occurs primarily via renal excretion. Both 5-ASA and acetylated metabolites are excreted in urine, with reported elimination half-lives ranging from approximately 8 to 20 hours, influenced by renal function status. Fecal excretion also contributes to elimination through unabsorbed drug and metabolites. Renal impairment may necessitate careful monitoring due to potential accumulation. Overall, olsalazine displays predictable elimination kinetics consistent with its prodrug design favoring local colonic activity.

Dosage Forms

Available Dosage Forms:
- Oral capsule (250 mg) formulation of Dipentum designed for targeted colonic delivery.

Dosages for Adults and Adolescents:
- The typical adult dose is 1 capsule (250 mg) taken orally twice daily with food, to maintain remission in patients with ulcerative colitis.
- Dose adjustments may be required based on patient tolerability and disease severity, although specific alternate dosing regimens are not routinely recommended.

Specific Patient Populations:
- In patients with renal impairment, careful clinical monitoring is advised due to drug excretion pathways.
- Pediatric use is restricted due to limited safety and efficacy data.
- Use is contraindicated in patients with hypersensitivity to salicylates or related compounds.
- Pregnant or breastfeeding women should consult a healthcare provider as safety has not been fully established.
- Concomitant administration with vaccines such as varicella may delay treatment initiation due to immunomodulatory potential.

Clinical Practice Guidelines:
- Always administer Dipentum with food to enhance tolerability and absorption.
- Patients should be advised to maintain adequate hydration to support renal function during therapy.
- Regular clinical and laboratory monitoring is recommended to identify adverse effects early.

Mechanism Of Action

Dipentum contains olsalazine, a prodrug that exerts its therapeutic effects via localized release of 5-aminosalicylic acid (5-ASA) in the colon. The primary molecular mechanism involves enzymatic cleavage by colonic bacterial azoreductases, which reduce the azo bond of olsalazine to release two molecules of active 5-ASA. This targeted drug delivery ensures high local concentrations of the anti-inflammatory agent specifically within the colonic mucosa, where ulcerative colitis pathology is concentrated.

At the cellular level, 5-ASA modulates multiple inflammatory pathways by inhibiting the production of pro-inflammatory mediators such as prostaglandins and leukotrienes via cyclooxygenase and lipoxygenase pathways. It scavenges reactive oxygen species and free radicals, which play a role in chronic mucosal inflammation. Additionally, 5-ASA inhibits nuclear factor kappa B (NF-κB) activation, a key transcription factor regulating the expression of numerous inflammatory cytokines and adhesion molecules.

Biochemically, 5-ASA reduces mucosal inflammation by suppressing cytokines like interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ). It may also promote epithelial barrier function and mucosal healing by modulating nitric oxide and superoxide production within inflamed tissues. These actions collectively decrease epithelial damage, immune cell infiltration, and overall inflammatory response associated with ulcerative colitis.

Clinically, the mechanism of olsalazine-derived 5-ASA allows for effective induction and maintenance of remission in mild to moderate ulcerative colitis. Compared to other 5-ASA formulations, olsalazine's prodrug nature targets drug release to the distal colon and rectum, which is a crucial site for disease activity. Research indicates olsalazine is comparable in efficacy to sulfasalazine but with reduced systemic side effects, as it does not release sulfapyridine. Clinical trials have demonstrated olsalazine’s ability to maintain remission rates with a favorable safety profile, making Dipentum a valuable therapeutic option in the management of ulcerative colitis.

Pharmacological Actions

Prodrug conversion by colonic bacteria to deliver active 5-aminosalicylic acid locally within the colon.
Inhibition of cyclooxygenase and lipoxygenase pathways, reducing synthesis of pro-inflammatory prostaglandins and leukotrienes.
Scavenging of reactive oxygen species and free radicals to minimize oxidative mucosal damage.
Suppression of nuclear factor kappa B (NF-κB)-mediated inflammatory gene expression.
Reduction of pro-inflammatory cytokines such as TNF-α, IL-1, and IFN-γ in colonic mucosa.
Enhancement of mucosal barrier integrity and promotion of epithelial healing.
Selective targeting of colonic inflammation with limited systemic absorption.
Reduction of neutrophil chemotaxis and inhibition of inflammatory cell infiltration.
Modulation of nitric oxide and superoxide production to decrease mucosal injury.
Maintenance of remission in mild to moderate ulcerative colitis.
Lower incidence of systemic adverse effects compared to sulfasalazine due to lack of sulfapyridine moiety.
Anti-inflammatory action primarily in the distal ileum and colon.
Minimal systemic immunosuppression, contributing to a favorable safety profile.

Therapeutic Or Clinical Uses

Treatment and maintenance of remission in mild to moderate ulcerative colitis in adults.
Management of chronic inflammatory bowel disease localized to the colon.
Alternative therapy for patients intolerant to sulfasalazine or other 5-ASA derivatives.
Reduction of colonic mucosal inflammation and epithelial damage in ulcerative colitis.
Potential use in preventing relapse in patients with quiescent ulcerative colitis.
Symptomatic management of bowel inflammation with localized drug delivery.
Adjunctive therapy in ulcerative colitis patients requiring aminosalicylate treatment.
Improvement of quality of life through maintenance of disease remission.
Off-label consideration for similar inflammatory colonic disorders under physician guidance.
Reduction of corticosteroid dependency in ulcerative colitis therapy.
Treatment option for patients with a contraindication to immunosuppressive or biologic agents.
Management of disease while minimizing systemic side effects.
Maintenance therapy to sustain mucosal healing and reduce need for surgery.
Therapeutic choice emphasizing favorable tolerability in long-term treatment.
Potential role in combination with other therapies for comprehensive disease control.

Side Or Adverse Effects

Diarrhea, which can be severe or persistent requiring medical evaluation.
Stomach pain or abdominal discomfort associated with gastrointestinal irritation.
Skin rash and itching, indicative of possible hypersensitivity reactions.
Signs of allergic reactions such as hives, facial swelling, or difficulty breathing.
Severe skin reactions including fever, sore throat, burning eyes, blistering, or peeling rash.
Worsening ulcerative colitis symptoms including fever, cramping, or bloody diarrhea.
Low blood cell counts manifesting as fever, chills, mouth sores, bruising, or unusual bleeding.
Liver dysfunction symptoms such as jaundice, dark urine, and upper right abdominal pain.
Kidney disorders including swelling, decreased urination, or flank pain suggestive of kidney stones.
Fatigue and muscle aches correlating with systemic hypersensitivity or drug reactions.
Nausea and vomiting following drug initiation or overdose.
Potential for photosensitivity increasing risk of sunburn; caution advised in patients with eczema or atopic dermatitis.
Rare but serious hypersensitivity involving multiple organ systems requiring immediate cessation.
Headache and dizziness as less common neurological side effects.
Possible elevation of liver enzymes and monitoring recommended during therapy.

Precautions

Do not use if allergic to olsalazine, balsalazide, mesalamine, sulfasalazine, or other salicylates including aspirin.
Inform healthcare providers about all medical conditions and medications before initiating therapy.
Delay treatment initiation if recent varicella (chickenpox) vaccination occurred within the past 6 weeks.
Use cautiously in patients with existing liver disease due to potential hepatotoxicity.
Monitor renal function closely, especially when co-administered with nephrotoxic drugs.
Avoid in individuals with known skin conditions such as eczema or atopic dermatitis without medical supervision.
Initiate treatment under close clinical observation in patients with a history of blood disorders.
Pregnant or breastfeeding women should consult a healthcare provider; safety in these populations is not well established.
Maintain adequate hydration during therapy to support kidney function.
Advise patients to take the medication with food to reduce gastrointestinal discomfort.
Avoid excessive sunlight exposure and use sun protection to reduce photosensitivity risk.
Review all concomitant medications to prevent potential drug interactions.
Do not discontinue therapy abruptly without medical consultation to prevent disease flare-ups.
Inform patients about signs of serious adverse reactions warranting immediate medical attention.
Routine laboratory monitoring, including blood counts and liver and renal function tests, is recommended.

Warnings

Risk of severe allergic reactions including anaphylaxis, requiring immediate medical intervention.
Potential for life-threatening skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis.
May cause worsening of ulcerative colitis symptoms; patients should contact their physician if symptoms worsen.
Serious hematologic adverse effects including leukopenia, thrombocytopenia, and neutropenia have been reported.
Hepatotoxicity risk necessitates monitoring for signs of liver injury during treatment.
Use with caution in patients with renal impairment due to risk of accumulation and toxicity.
Possible interference with varicella vaccine efficacy or increased immunosuppression post-vaccination.
Dipentum may affect laboratory tests, potentially altering results; inform laboratory personnel of usage.
Avoid concurrent use with nephrotoxic drugs or drugs that may exacerbate blood disorders without medical oversight.
Potential for photosensitivity reactions; patients should avoid tanning beds and prolonged sun exposure.
Should not be used in patients with known hypersensitivity to the drug or related compounds.
Discontinue therapy immediately if severe skin rash, fever, or jaundice develops.
Close clinical monitoring is required to detect early signs of systemic hypersensitivity or organ dysfunction.
Not recommended for pediatric use due to insufficient safety data.
Risk of drug interactions necessitates thorough medication reconciliation before initiation.

Contraindication

Known hypersensitivity or allergy to olsalazine or its components.
Allergy to other 5-aminosalicylates such as mesalamine, balsalazide, or sulfasalazine.
Hypersensitivity to salicylates including aspirin and related compounds such as Novasal or Tricosal.
Severe liver disease or active liver failure at baseline.
Severe renal impairment without close monitoring due to risk of toxicity.
History of serious skin reactions or systemic hypersensitivity to aminosalicylate drugs.
Use in patients receiving varicella vaccination within the previous 6 weeks without consultation.
Known blood dyscrasias or significant hematologic abnormalities without medical supervision.
Patients with severe diarrhea or colitis exacerbation should withhold olsalazine until evaluation.
Contraindicated in patients with previous severe allergic reactions to azo compounds.
Not suitable for pediatric patients under current labeling guidance.
Pregnant or breastfeeding women only if clearly needed and under physician supervision.
Presence of active infections that may be exacerbated by immunomodulatory effects.
Concomitant use with certain nephrotoxic drugs without stringent monitoring is contraindicated.
Use with caution or avoidance in patients with skin disorders prone to photosensitive reactions.

Drug Interactions

Concurrent use with azathioprine or 6-mercaptopurine may increase risk of myelosuppression.
Interactions with thioguanine can enhance hematologic toxicity requiring careful monitoring.
Co-administration with blood thinners such as heparin, warfarin, Coumadin, or Jantoven increases bleeding risk.
Concurrent use with nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen may exacerbate renal toxicity.
Co-use with nephrotoxic agents can increase risk of renal impairment.
Dipentum may alter the efficacy or safety profile of certain immunosuppressants and chemotherapy drugs.
Potential interaction with other salicylate-containing products enhancing adverse effects.
Interactions with vaccines, particularly live viruses, may impair immune response or delay treatment.
Drugs affecting renal clearance can alter Dipentum elimination and toxicity profile.
Herbal supplements with anticoagulant effects may potentiate bleeding when combined.
Agents that acidify or alkalinize urine may affect renal excretion and drug levels.
Interactions with drugs metabolized by N-acetyltransferase enzymes may influence 5-ASA metabolism.
Some drugs may affect gastrointestinal flora, potentially altering olsalazine activation.
Concomitant use of potent enzyme inducers or inhibitors may theoretically impact drug metabolism.
Regular review of all prescription, over-the-counter, and herbal medications is advised to detect interactions.

Preparations Of The Drug

Dipentum oral capsules 250 mg: delayed-release formulation designed for colonic drug delivery.
Available in prescription form only with detailed patient information leaflets included.
Should be stored at room temperature, protected from moisture and heat.
Packaged in blister strips or bottles to maintain drug stability.
Administered orally, typically given twice daily with food to enhance tolerability.
No topical, injectable, or intravenous formulations available for olsalazine.
Packaging includes instructions to maintain hydration during therapy.
Clear labeling to avoid confusion with other aminosalicylates or salicylate products.
Prepared under Good Manufacturing Practice (GMP) standards to assure purity and potency.
Formulation developed to minimize sulfapyridine-related adverse effects compared to sulfasalazine.
Designed to release active drug specifically in the distal ileum and colon.
Accompanied by detailed prescribing information highlighting warnings, precautions, and dosage.
Shelf life typically 24-36 months if stored properly away from direct light and moisture.
Includes NSAID and salicylate allergy warnings in packaging materials.
Patient adherence aids such as calendars or dosing reminders may be available with certain packaging.